<DOC>
	<DOCNO>NCT01060189</DOCNO>
	<brief_summary>Antifibrinolytic drug use decrease perioperative bleeding allogeneic transfusion . The extensively studied antifibrinolytic drug aprotinin efficacious expensive , prove link high risk serious side effect include renal problem , myocardial event , stroke patient undergo CABG . After secession aprotinin 2007 , mark increase blood loss transfusion cardiac surgery take place . An effective secure hemostatic agent badly need . Ulinastatin , urinary trypsin inhibitor ( UTI ) , secrete Kunitz-type protease inhibitor wide inhibition spectrum , include plasmin . Limited study offer clue antifibrinolytic effect . Tranexamic acid apply year convince efficacy safety . The objective study evaluate hemostatic anti-inflammatory effect ulinastatin tranexamic acid cardiac surgery .</brief_summary>
	<brief_title>Hemostatic Anti-Inflammatory Effects Ulinastatin Tranexamic Acid Cardiopulmonary Bypass Cardiac Surgery</brief_title>
	<detailed_description />
	<mesh_term>Hemostatics</mesh_term>
	<mesh_term>Tranexamic Acid</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<mesh_term>Urinastatin</mesh_term>
	<criteria>Atrial ventricular septum defect patient require cardiac surgery CPB Rheumatic recessive valvular patient require valvular repair replacement CPB Coronary artery disease patient require coronary revascularization CPB Nonprimary cardiac surgery Definite liver renal dysfunction Disorder coagulation function Allergy Pregnancy lactation Disabled spirit law Fatal condition tumour</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>ulinastatin</keyword>
	<keyword>tranexamic acid</keyword>
	<keyword>cardiac surgery procedure</keyword>
	<keyword>hemostasis</keyword>
	<keyword>anti-inflammation</keyword>
</DOC>